Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. - Wikidata - awgldk - TriplyDB

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

http://www.wikidata.org/entity/Q46708731

about

Trial watch - inhibiting PARP enzymes for anticancer therapy New and emerging factors in tumorigenesis: an overview Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Current treatment of early breast cancer: adjuvant and neoadjuvant therapy Status of adjuvant endocrine therapy for breast cancer.Long-term risk of medical conditions associated with breast cancer treatment Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer Adverse effects of azacitidine: onset, duration, and treatment.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Adjuvant Systemic Therapy of Breast Cancer.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.Ethics of ongoing cancer care for patients making risky decisions Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.Aromatase inhibitor treatment for breast cancer: short-term effect on bone health Adjuvant hormonal therapy in premenopausal women with breast cancer.Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncolog Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.Tamoxifen: the drug that came in from the cold.Surgical oophorectomy for breast cancer: back to the future.Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

P2860

Q26745673-B3088725-67BD-4042-B674-0D96BD3AC2E3 Q26801253-ACA64C2A-C6AC-4936-8B8E-6818B7437442 Q27002430-4096692D-F4AD-405B-8818-D2CB58EDE7C1 Q27011658-484E10C2-031F-4D33-BD54-2ADAF77651FE Q33739138-A90CD8AC-403B-4B4A-9D48-1C8555141C91 Q33895877-2578727B-445E-44CE-BCEF-185F840ED603 Q34082909-3A26E5A1-ED65-49F7-A555-6DC95C592930 Q34096283-EE4FB873-9B4D-49A4-AC9C-4EF5FF84D22E Q34193934-B81BBF73-B902-4E16-8D28-AA0B6498D5FA Q34233815-79B03EC2-29D3-4533-BD3D-7D14A41995EB Q34303205-4CBC677C-7183-4144-9C7A-3B1D1ED28F7C Q34403564-77F921E5-6293-4C36-8E0F-1542DF31407F Q34655579-2F81237A-588F-4FE7-B7F4-E88FD45DF107 Q34774649-6E35346A-2F61-4858-81FE-93DB2F468422 Q34873249-98277EDA-BE8B-4386-B614-57C52B088FC9 Q35095595-BA227C5C-8E51-4C4E-85EF-865F4F0186C5 Q35106041-F68F0681-B41A-40AD-8575-99E74E736500 Q35565585-C9758806-D62C-426D-B7B0-ED50EAC5C0D1 Q35642388-B9359498-004A-4071-8EA1-666D913C8234 Q35720004-3E95BEC1-B09A-45C6-A668-BE9D4B9FEFB0 Q35808358-5F4FC7E5-B6ED-4AE3-A640-DE84B7A4C87B Q35847450-95E24A0C-671A-4D4B-93C2-901F3AA7FC75 Q35925132-1A61CD9D-A902-45DA-9B14-62150A52BBE2 Q36070063-7467E1D6-0E19-426D-BDBB-577EEF8F6FF0 Q36226336-0CFD5EA4-381B-443E-B4D3-58E38B9D5382 Q36321147-04C206ED-424F-42B1-BCA6-EC5DF5A1F3B7 Q36452858-F85B6D6C-69F1-45A8-943A-E0429115446B Q36457989-2B6ED9DD-CFC4-49F3-A72D-AAD458CCDB91 Q37103057-4819CFA2-7D08-4597-A5A4-818592B5E53D Q37169337-69AB93AD-3015-4791-9FE2-45AA351AC09E Q37199625-E6FE629B-48C2-4A04-A760-39796F5F8FEE Q37263046-6347E282-D009-4147-9257-89961C5FFB2A Q37292419-4069A5AE-F64C-4615-9E3F-38344194B2BC Q37316233-28476127-1FFC-4C17-A33C-C58F1449CA52 Q37345339-82964BDF-A573-44E6-995E-B6E767DD5F50 Q37351996-16406A47-38EE-41FB-B0CF-BB91BF7553AF Q37354647-ABC12853-CBBF-4027-BADE-8B3C5800D2CF Q37355574-D6598CA7-1AC8-45B2-9EEE-6E25ABA57743 Q37431101-42A0E63A-5355-4D85-85DB-78C28B6F0EDB Q37463330-2FCAFB45-1FB5-4B9C-B347-CC4ED16AD178

P2860

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

http://www.wikidata.org/entity/Q46708731

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@en

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@nl

type

label

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@en

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@nl

prefLabel

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@en

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@nl

P1433

Q46708731-15D9CB9D-5BB9-43FA-A32C-FED35EA5B3CD

P1476

Q46708731-02C84D2E-4CF3-49FA-926B-253A8FC86E31

P2093

Q46708731-03EA2F84-9E98-4BB6-B061-773C4B2B46E4

Q46708731-280D7265-8FC9-4840-986D-0E14BBE1DE87

Q46708731-2D489709-6969-4300-8D2F-56925028EBAE

Q46708731-42704BE2-9B2F-4A6F-8AC0-2F2840C0D2D2

Q46708731-4326C144-D28F-4011-BE5F-41C3F39AE307

Q46708731-75E169B3-4372-4223-AA9E-1C498896E52E

Q46708731-7E46F1AD-D890-4C7D-AD9E-52D36E24C24A

Q46708731-82F6E2FA-3E84-4E1C-9982-DCE920C324B6

Q46708731-87B9FC05-48DF-4783-A398-43D8049CA469

Q46708731-A5FCD72E-DF65-47D3-8288-E500D8C6FD9E

P304

Q46708731-9C478F16-37F5-4F78-9CCE-B19DE5FE6ED5

P31

Q46708731-A36ED31C-7892-44A6-B243-9E9499D5ED78

P356

Q46708731-161D10CB-ED9E-4157-89CB-AA9943D454B9

P407

Q46708731-C871D609-3900-49D3-B9D2-32B49A19C445

P433

Q46708731-1C27A7B9-73D9-4504-BE69-117511E950AB

P478

Q46708731-54B0340B-23FE-407F-966E-D71B91272153

P50

Q46708731-FA8A8B51-8C03-4645-B4E3-99804F5C05DF

P577

Q46708731-7F12E793-3077-4B25-9803-D472DA35BCCC

P698

Q46708731-21E74501-14DE-42F2-96D1-B6585D482A4F

P356

JCO.2007.11.6798

P1433

Journal of Clinical Oncology

P1476

Late extended adjuvant treatme ...... complete 5 years of tamoxifen.

@en

P2093

David A Cameron

http://www.w3.org/2001/XMLSchema#string

Dongsheng Tu

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Hyman B Muss

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Abrams

http://www.w3.org/2001/XMLSchema#string

Joseph L Pater

http://www.w3.org/2001/XMLSchema#string

Kathleen I Pritchard

http://www.w3.org/2001/XMLSchema#string

Lois E Shepherd

http://www.w3.org/2001/XMLSchema#string

Martine J Piccart

http://www.w3.org/2001/XMLSchema#string

P304

1948-1955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.11.6798

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18332475

http://www.w3.org/2001/XMLSchema#string